Ning‐Chi Wang
- Molecular Medicine top 5%
- Infectious Diseases top 5%
- HIV/AIDS drug development and treatment 5
- Endocrinology top 5%
- Hepatology top 10%
- Hepatitis C virus research 6
-
- Streptococcal Infections and Treatments 6
-
- Hepatitis B Virus Studies 6
- Pneumocystis jirovecii pneumonia detection and treatment 5
-
- HIV Research and Treatment 6
-
- Bacterial Identification and Susceptibility Testing 5
-
- Infectious Diseases and Tuberculosis 5
Ning‐Chi Wang
46 papers receiving 628 citations
Peers
Comparison fields: 5 of 79
- Molecular Medicine 87
- Infectious Diseases 312
- Endocrinology 73
- Applied Microbiology and Biotechnology 23
- Hepatology 88
Countries citing papers authored by Ning‐Chi Wang
This map shows the geographic impact of Ning‐Chi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ning‐Chi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ning‐Chi Wang more than expected).
Fields of papers citing papers by Ning‐Chi Wang
This network shows the impact of papers produced by Ning‐Chi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ning‐Chi Wang. The network helps show where Ning‐Chi Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ning‐Chi Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 4 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 2 | |
| 4 | 2022 | 5 | |
| 5 | 2022 | 3 | |
| 6 | 2021 | 0 | |
| 7 | 2018 | 18 | |
| 8 | 2018 | 10 | |
| 9 | 2018 | 3 | |
| 10 | 2017 | 14 | |
| 11 | 2014 | 6 | |
| 12 | 2012 | 9 | |
| 13 | 2012 | 24 | |
| 14 | 2011 | 17 | |
| 15 | 2010 | 6 | |
| 16 | 2010 | 35 | |
| 17 | Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. | 2008 | 30 |
| 18 | 2008 | 5 | |
| 19 | 2008 | 4 | |
| 20 | 2006 | 15 |
About Ning‐Chi Wang
Ning‐Chi Wang is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 48 papers that have together received 651 indexed citations. Recurring topics across this work include Streptococcal Infections and Treatments (6 papers), Hepatitis B Virus Studies (6 papers), HIV Research and Treatment (6 papers), Hepatitis C virus research (6 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers), HIV/AIDS drug development and treatment (5 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Infectious Diseases and Tuberculosis (5 papers). The work is most often cited by research in Molecular Medicine (87 citations), Infectious Diseases (312 citations) and Endocrinology (73 citations). Ning‐Chi Wang has collaborated with scholars based in Taiwan, Australia and Malaysia. Frequent co-authors include Feng‐Yee Chang, Jung‐Chung Lin, Ming-Yieh Peng, Te‐Yu Lin, Sheng-Kang Chiu, Ya‐Sung Yang, Kuo‐Ming Yeh, Chien‐Ching Hung, Shih‐Ping Lin and Shu‐Hsing Cheng. Their work appears in journals such as Journal of Microbiology Immunology and Infection, The American Journal of the Medical Sciences, PLoS ONE, Modern Rheumatology and International Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.